Biotech stocks have been dropping in value since early February, likely depressed by some regulatory and drug pricing concerns, but some analysts think the sector will rebound later this year, partly on the back of M&A deals and new product releases.... [+]
David Nierengarten, a biotech and biopharmaceuticals analyst at Wedbush Securities in Los Angeles, toldthat concerns over stalled new drug approvals by the Food and Drug Administration are likely weighing on the biotech sector.
Sverige Senaste nytt, Sverige Rubriker
Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.
After Roaring In 2020, Biotech Stocks Now Weighed Down By Merger Scrutiny, FDA Approval Delays And Possible Drug Pricing LegislationI have more than 20 yrs experience in writing about financial markets. I am especially interested in history and literature.
Läs mer »
After Roaring In 2020, Biotech Stocks Now Weighed Down By Merger Scrutiny, FDA Approval Delays And Possible Drug Pricing LegislationAfter roaring in 2020, biotech stocks are now weighed down by merger scrutiny, FDA approval delays and possible drug pricing legislation
Läs mer »